WO2003047521A3 - Composition and method for treatment of otitis media - Google Patents

Composition and method for treatment of otitis media Download PDF

Info

Publication number
WO2003047521A3
WO2003047521A3 PCT/US2002/038366 US0238366W WO03047521A3 WO 2003047521 A3 WO2003047521 A3 WO 2003047521A3 US 0238366 W US0238366 W US 0238366W WO 03047521 A3 WO03047521 A3 WO 03047521A3
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
therapeutically active
lipid crystals
lipid
lumen
Prior art date
Application number
PCT/US2002/038366
Other languages
French (fr)
Other versions
WO2003047521A2 (en
Inventor
Alan Mautone
Original Assignee
Scient Dev And Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient Dev And Res Inc filed Critical Scient Dev And Res Inc
Priority to EP02784684A priority Critical patent/EP1461090A4/en
Priority to JP2003548782A priority patent/JP2005511648A/en
Publication of WO2003047521A2 publication Critical patent/WO2003047521A2/en
Publication of WO2003047521A3 publication Critical patent/WO2003047521A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Abstract

A process, composition and method for increasing and enhancing mammalian eustachian tube lumen patency and pressure equalization performance is disclosed wherein an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, and proteins, in powder form, and one or more propellants, in which the lipid surfactants and spreading agents are not soluble, are administered through a mammalian airway orifice. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited within a subject mammalian eustachian tube whereupon said lipid crystals come into contact with lumen surfaces of the tube forming an amorphous spread film thereupon substantially decreasing the opening pressure of the lumen. In a second preferred embodiment, a therapeutically active agent effective in the treatment of otitis media is added to the mixture of lipid crystals and upon administration of said aerosol mixture, the amorphous spread film formed thereby carries said therapeutically active agent through the eustachian tube to the tissues of the middle ear. In an alternate preferred embodiment, the afore-mentioned reduction of surface tension and delivery of therapeutically active agents is provided by a mixture of lipid crystals comprised of surfactant(s), therapeutically active agents and a propellant in which such other components are not soluble.
PCT/US2002/038366 2001-12-04 2002-11-29 Composition and method for treatment of otitis media WO2003047521A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02784684A EP1461090A4 (en) 2001-12-04 2002-11-29 Composition and method for treatment of otitis media
JP2003548782A JP2005511648A (en) 2001-12-04 2002-11-29 Compositions and methods for the treatment of otitis media

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/011,344 2001-12-04
US10/011,344 US6676930B2 (en) 1999-11-28 2001-12-04 Composition and method for treatment of otitis media

Publications (2)

Publication Number Publication Date
WO2003047521A2 WO2003047521A2 (en) 2003-06-12
WO2003047521A3 true WO2003047521A3 (en) 2003-09-18

Family

ID=21749979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038366 WO2003047521A2 (en) 2001-12-04 2002-11-29 Composition and method for treatment of otitis media

Country Status (4)

Country Link
US (2) US6676930B2 (en)
EP (1) EP1461090A4 (en)
JP (1) JP2005511648A (en)
WO (1) WO2003047521A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
KR100717433B1 (en) * 2003-03-20 2007-05-14 파마시아 코포레이션 Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20070173463A1 (en) * 2006-01-20 2007-07-26 Brechtelsbauer Paul B Method and composition for treating otitis media
EP1988850B1 (en) * 2006-02-27 2016-10-12 AHM Technologies, Inc. Eustachian tube device
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
WO2008057248A2 (en) 2006-10-26 2008-05-15 Next Breath Llc Phospholipid-based inhalation system
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090197956A1 (en) * 2008-02-04 2009-08-06 Arbor Pharmaceuticals, Inc. Treatment of acute otitis media with xylitol and n-acetylcysteine
CA2727432C (en) 2008-06-12 2016-10-11 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
EP2346324A4 (en) * 2008-10-06 2012-10-10 Microbial Defense Systems Llc Antimicrobial composition and methods of making and using same
US11033624B2 (en) 2010-06-02 2021-06-15 Novaflux Inc. Medical item for prevention and treatment of ear infection
CA2835211C (en) 2011-05-10 2019-09-24 Next Science, Llc Antimicrobial solid and methods of making and using same
WO2015168642A1 (en) 2014-05-02 2015-11-05 Labib Mohamed E Drug-releasing device usable in mucosal body cavities
WO2017095905A1 (en) * 2015-11-30 2017-06-08 Flesher Gregory J Compositions and methods for otologic prophylaxis and treatment
WO2020154074A1 (en) * 2019-01-23 2020-07-30 Alrich Partners, Inc. Method for enhancing eustachian tube patency and treatment of otitis media

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158441B2 (en) 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
US5141674A (en) 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
ATE78158T1 (en) 1985-05-22 1992-08-15 Liposome Technology Inc METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES.
US4826821A (en) 1985-06-26 1989-05-02 The Regents Of The University Of California Lung surfactant compositions
SE462894B (en) 1985-10-28 1990-09-17 Biogram Ab MICROCAPPLES, PROCEDURES FOR PREPARING THEREOF AND USING
US5013720A (en) 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
SE8603812D0 (en) 1986-09-12 1986-09-12 Draco Ab ADMINISTRATION OF LIPOSOMES TO MAMMALS
CA1338736C (en) 1986-12-05 1996-11-26 Roger Baurain Microcrystals containing an active ingredient with affinity for phospholipids and at least one phospholipid; process for preparing the same
IT1203873B (en) 1987-04-08 1989-02-23 Chiesi Farma Spa PHARMACEUTICAL COMPOSITIONS THAT THE NATURAL PULMONARY SURFACTANT CONTAIN. PREPARATION METHOD E
JP2656944B2 (en) 1987-04-30 1997-09-24 クーパー ラボラトリーズ Aerosolization of protein therapeutics
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
JPH01258620A (en) 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd Local pharmaceutical for otopathy
MX9203504A (en) 1988-04-20 1992-07-01 Liposome Co Inc AGENT COMPLEX: HIGH PROPORTION ACTIVE LIPID.
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5134129A (en) 1989-03-15 1992-07-28 Board Of Regents, The University Of Texas System Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0724386A1 (en) 1991-04-29 1996-08-07 DI BARTOLOMEO, Joseph R. Composition and method for treatment of patulous eustachian tube syndrome and atrophic rhinitis
GB9120005D0 (en) 1991-09-19 1991-11-06 Wellcome Found Method of administering phospholipid dispersions
IS1796B (en) 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
DE4323636A1 (en) 1993-07-15 1995-01-19 Hoechst Ag Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation
CA2213638C (en) 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
WO1996027393A1 (en) 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US6129934A (en) 1995-06-07 2000-10-10 Ony, Inc. Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
AU2322097A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
KR20000048812A (en) 1996-10-01 2000-07-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Use of Mupirocin for the Manufacture of a Medicament for the Treatment of Bacterial Infections Associated with Colonisation of the Nasopharynx by Pathogenic Organisms
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
EP1054679B1 (en) * 1997-12-24 2003-02-12 Britannia Pharmaceuticals Limited Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6297227B1 (en) 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6093417A (en) 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6645467B2 (en) * 1999-11-28 2003-11-11 Scientific Development And Research, Inc. Composition and method for decreasing upper respiratory airway resistance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5306483A (en) * 1989-07-27 1994-04-26 Scientific Development & Research, Inc. Phospholipid delivery system
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1461090A4 *

Also Published As

Publication number Publication date
WO2003047521A2 (en) 2003-06-12
JP2005511648A (en) 2005-04-28
EP1461090A4 (en) 2010-12-22
US6676930B2 (en) 2004-01-13
US20020064503A1 (en) 2002-05-30
US20040001868A1 (en) 2004-01-01
EP1461090A2 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
CA2392367A1 (en) Composition and method for treatment of otitis media
WO2003047521A3 (en) Composition and method for treatment of otitis media
JP2003514842A5 (en)
CA2268927A1 (en) Aqueous-based pharmaceutical composition
JP2779165B2 (en) Compositions and methods
KR950013499A (en) Medical Aerosol Formulations
JP2005511648A5 (en)
AU4717199A (en) Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2005037246A3 (en) Aqueous aerosol preparation
CA2225398A1 (en) Pharmaceutical composition comprising albumin as an active ingredient
IE68451B1 (en) Nitroglycerin pump spray
HU228487B1 (en) Pharmaceutical aerosol composition
WO2003055410A3 (en) Composition and method for treatment of otitis externa
JP2797069B2 (en) Ophthalmic pharmaceutical composition and method of administration thereof
MXPA02002485A (en) Proteinic drug delivery system using membrane mimetics.
Joondeph et al. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy
WO2003047522A3 (en) Composition and method for decreasing upper respiratory airway resistance
AU1250999A (en) Use of surface active agent for the manufacture of a medicament for treatment ofdisorders of the middle ear
Billowria et al. Topical advances in mucoadhesive ocular drug delivery system
CN105476730B (en) A kind of medicament nano lipid carrier intraocular lens system and its application
US20090270335A1 (en) Collyrium for dry eye
WO2005072776A3 (en) Liposomal formulations of the antineoplastic agents
Robin et al. Preliminary evaluation of two experimental surgical adhesives in the rabbit cornea
JP3045606B2 (en) Skin cosmetic composition
WO1996001128A3 (en) Low-dose steroid tablets containing gallic acid esters as antioxidant agent, process for the manufacture of said tablets, and uses of said tablets

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA CN JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003548782

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002784684

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002784684

Country of ref document: EP